The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium tuberculosis In Vivo

Lassomycin, a Ribosomally Synthesized Cyclic Peptide, Kills Mycobacterium tuberculosis by Targeting the ATP-Dependent Protease ClpC1P1P2

(2014) Ekaterina Gavrish et al.   CHEMISTRY & BIOLOGY

Discovery and Characterization of the Tuberculosis Drug Lead Ecumicin

(2014) Wei Gao et al.   ORGANIC LETTERS

Mycobacterial Esx-3 Requires Multiple Components for Iron Acquisition

(2014) M. S. Siegrist et al.   mBio

Structural Basis of Mycobacterial Inhibition by Cyclomarin A

(2013) Dileep Vasudevan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

(2012) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The active ClpP protease fromM. tuberculosisis a complex composed of a heptameric ClpP1 and a ClpP2 ring

(2012) Tatos Akopian et al.   EMBO JOURNAL

Mycobacterium abscessus: a new antibiotic nightmare

(2012) R. Nessar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

(2012) Christian Lienhardt et al.   JOURNAL OF INFECTIOUS DISEASES

Bacterial proteolytic complexes as therapeutic targets

(2012) Ravikiran M. Raju et al.   NATURE REVIEWS DRUG DISCOVERY

New insights on the structure of the anti-TB peptide H14: Crystal structure, 1H NMR full spin analysis, and biosynthetic pathway

(2012) W Gao et al.   PLANTA MEDICA

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis

(2012) Scott G. Franzblau et al.   TUBERCULOSIS

Mycobacterium tuberculosis ClpP1 and ClpP2 Function Together in Protein Degradation and Are Required for Viability in vitro and During Infection

(2012) Ravikiran M. Raju et al.   PLoS Pathogens

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

(2011) Esther K. Schmitt et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Nitroimidazoles for the treatment of TB: past, present and future

(2011) Tathagata Mukherjee et al.   Future Medicinal Chemistry

Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis

(2011) W. Shi et al.   SCIENCE

High-Resolution Phenotypic Profiling Defines Genes Essential for Mycobacterial Growth and Cholesterol Catabolism

(2011) Jennifer E. Griffin et al.   PLoS Pathogens

Picking Up the Pace — Scale-Up of MDR Tuberculosis Treatment Programs

(2010) Salmaan Keshavjee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents

(2010) B. Zhou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease

(2009) Janine Kirstein et al.   EMBO Molecular Medicine

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

(2009) Evan W Orenstein et al.   LANCET INFECTIOUS DISEASES

Target identification using drug affinity responsive target stability (DARTS)

(2009) B. Lomenick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mycobacterium tuberculosis ClpC1

(2008) Narayani P. Kar et al.   FEBS Journal